| Course | HCR 563 Fundamentals of Regulatory Affairs |
|---|---|
| Module | Module 3 |
| Paper type | Regulatory slide presentation |
| Length | About 602 words, 5 pages |
| Format | APA 7 slide deck with speaker notes |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 563 Module 3
Bringing a Device to Japan: Classes, Pathways and Quality Requirements
Student Name
MS in Regulatory Science, Arizona State University
HCR 563: Fundamentals of Regulatory Affairs
Instructor Name
Month Day, Year
Slide 1: Bringing a Device to Japan
Classes, pathways and quality requirements for a U.S. manufacturer entering the Japanese market.
Speaker notes: Japan is one of the largest device markets in the world, and its system differs from the FDA's in ways that catch U.S. companies off guard. This deck walks through it step by step.
Slide 2: Who Regulates
The health ministry (MHLW) makes approval decisions. The Pharmaceuticals and Medical Devices Agency (PMDA) reviews applications and runs postmarket safety. Registered certification bodies handle many mid-risk devices.
Speaker notes: Three actors share the work. The ministry decides, the PMDA reviews and monitors safety and private registered certification bodies certify devices for which national standards exist (Pharmaceuticals and Medical Devices Agency [PMDA], n.d.).
Slide 3: Four Risk Classes
Class I: extremely low risk. Class II: low risk. Class III: medium risk. Class IV: high risk.
Speaker notes: Japan's classes run from I to IV, one more tier than the three-class U.S. system described in the course text (Pacifici & Bain, 2018). A class IV device in Japan, such as an implantable heart valve, roughly corresponds to an FDA class III device.
Slide 4: Three Routes to Market
Class I: notification to the PMDA. Class II and III: third-party certification where certification standards exist, otherwise ministry approval. Class IV: ministry approval.
Speaker notes: The route follows the class. Notification is a filing, not a review. Certification uses published standards. Approval means a full PMDA review and a ministry decision.
Slide 5: The Marketing Authorization Holder
A foreign manufacturer cannot hold approval directly. It must act through a Japanese Marketing Authorization Holder responsible for efficacy, safety and quality.
Speaker notes: This is the biggest structural difference from the U.S. system. The holder files the application, holds the approval and answers for postmarket safety, so choosing the holder is a strategic decision (PMDA, n.d.).
Slide 6: Foreign Manufacturer Registration
Manufacturing sites outside Japan must be registered with the Japanese authorities before the device can be approved or certified.
Speaker notes: Registration is separate from product approval. Plan for it early, because a missing site registration can hold up an otherwise complete application.
Slide 7: Quality Management System
Japan's quality system ordinance is aligned with ISO 13485. Conformity is assessed for class II to IV devices, often through document review and sometimes on-site inspection.
Speaker notes: A U.S. company that already meets ISO 13485 has most of what Japan expects, but the evidence must be organized for the Japanese review and kept current through periodic renewals.
Slide 8: Timing and Lag
Review times vary by class and pathway. Studies of drug delivery devices find Japan often approves presentations in steps, adding months of lag compared with the United States.
Speaker notes: In biologic-device combination products, multidose pens and cartridges lagged by about two years in Japan while autoinjectors lagged about ten months, and Japan often approved device presentations one at a time rather than together (Mochizuki & Maeda, 2026).
Slide 9: Planning Checklist for a U.S. Company
1. Confirm the Japanese class. 2. Choose a Marketing Authorization Holder. 3. Register foreign sites. 4. Map ISO 13485 evidence to the Japanese ordinance. 5. Translate labeling into Japanese. 6. Plan postmarket reporting through the holder.
Speaker notes: These six steps cover the decisions that most often delay entry. Steps two and three should start in parallel with product testing.
Slide 10: Key Takeaways
Four classes, three routes. A Japanese holder is mandatory. Quality evidence must be organized for Japan. Plan for staged approvals.
Speaker notes: Japan rewards preparation. The device science may be the same as in the U.S., but the people, paperwork and sequence are different. Thank you.
References
Mochizuki, M., & Maeda, H. (2026). Approval lag and loss for biologic-device combination products in Japan and the United States. Frontiers in Medical Technology, 8, 1924169. https://doi.org/10.3389/fmedt.2026.1924169
Pacifici, E., & Bain, S. (2018). An overview of FDA regulated products: From drugs and cosmetics to food and tobacco. Academic Press.
Pharmaceuticals and Medical Devices Agency. (n.d.). Regulations and approval/certification of medical devices. Retrieved October 10, 2026, from https://www.pmda.go.jp/english/review-services/reviews/0004.html
Reading the HCR 563 Module 3 assignment instructions
Assignment 1 in HCR 563 is due in Week 3, the medical device module, and asks for a slide presentation that documents the device registration and quality process of a country not regulated by the FDA, with Canada excluded. The course text, Pacifici and Bain's An Overview of FDA Regulated Products, explains the U.S. device system, which gives you a point of comparison throughout. Choose a country with clear public guidance from its regulator, such as Japan, Brazil, Australia, South Korea or a European Union member state under the Medical Device Regulation, so your facts can be checked. A strong deck covers who regulates, how devices are classified, the routes to market by class, any requirement for a local representative or license holder, quality system expectations, timelines and practical steps for a company entering the market. Put explanation and citations in the notes so each slide stays brief.
Inside the HCR 563 Module 3 example
The deck opens with the country and the audience, then names the three regulatory actors in Japan and what each does. Classification and the three routes to market follow on separate slides so the logic from class to route is clear. Two slides cover the requirements that most differ from U.S. practice: the Marketing Authorization Holder and foreign site registration. A quality system slide connects Japan's ordinance to ISO 13485. A timing slide uses a published study of approval lag. A planning checklist turns the content into actions for a U.S. company, and the final slide summarizes four takeaways in short phrases. The notes cite the regulator's own page, so facts can be checked.
Where the marks sit in the HCR 563 Module 3 rubric
Assignment 1 is one of four papers and assignments that share 400 points in HCR 563. A strong deck chooses an eligible country, explains its regulators, classification and routes to market accurately, covers the quality system and any local holder or representative requirement, compares the system with the FDA's where helpful, uses current official sources and presents the material in clean slides with useful notes. Points go when facts come from consulting blogs rather than the regulator, when classification and pathways are confused, when quality requirements are missing and when slides are crowded with text. Graders value decks that end with practical steps, since the assignment is about the process a company would follow.
HCR 563 Module 3 help: mistakes that cost marks
Start on the regulator's English-language pages and build your outline from them. Map the country's classes to the FDA's so your audience has a reference point. Give the local holder or representative requirement its own slide; it is often the biggest surprise. Connect quality expectations to ISO 13485. Include timelines with a source. End with a checklist. Keep slides short and use notes for detail. If you are choosing between countries, the desk can suggest ones with complete English guidance. Present the country's process in the order a company would experience it, from classification to postmarket duties. Avoid slides that simply list laws; explain what each requirement means for a manufacturer. Verify each fact on the regulator's own English-language pages, not a consultant's summary.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 563 and MS in Regulatory Science sample papers
- HCR 563 Module 4: Assignment 2: Building Quality Into Clinical Trials
- HCR 563 Module 5: Assignment 3: Annotated Bibliography on Decentralized Trials
- HCR 579 Module 7: Ethical Paper: Precision Medicine
- HCR 555 Module 6: Assignment 5: A Pharmacogenomic Risk-Minimization Plan
- HCR 576 Module 5: Paper: A Recent Drug Recall and the FDA Process
- HCR 564 Module 4: Paper 1: Critique of Future Developments in Global Therapeutics
HCR 563 Module 3 questions, answered
Where can I find a free HCR 563 Module 3 sample paper?
This page has a full HCR 563 Assignment 1 sample: a slide deck on Japan's medical device registration and quality process.
How are medical devices classified in Japan?
In four classes, from Class I for extremely low risk to Class IV for high risk.
What is a Marketing Authorization Holder in Japan?
The Japanese company that files for and holds a device's approval or certification and answers for its quality and safety.
Which countries can I use for HCR 563 Assignment 1?
Any country whose device market is not regulated by the FDA, except Canada.
Which textbook does HCR 563 use?
Pacifici and Bain's An Overview of FDA Regulated Products.